The report, “The Multiple Sclerosis Therapeutics Market is segmented By Disease Type (Relapsing-Remitting MS, Secondary-Progressive MS, Primary-Progressive MS, and Clinically Isolated Syndrome), By Drug Class (Disease-Modifying Therapies, Corticosteroids, Monoclonal Antibodies, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region - Global Forecast to 2033”. multiple sclerosis therapeutics market size reached US$29.09 billion in 2025 and is expected to reach to US$46.22 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2026-2033.
The European Commission recently approved Sanofi’s Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis without relapses in the last two years. That patient group matters because secondary progressive multiple sclerosis is one of the most difficult areas of the disease to treat.
For years, the multiple sclerosis market has been shaped mainly by therapies that reduce relapses and inflammatory activity. These drugs transformed care for many patients with relapsing forms of multiple sclerosis. But the market has remained weaker in progressive disease, where disability can worsen steadily even without visible relapses. That is why Cenrifki matters. It gives Sanofi a position in a segment where there is significant unmet need and fewer competitive options. It also validates a broader industry shift toward therapies that target the biology of disability accumulation rather than only acute inflammatory activity.
Request for Exclusive Sample: https://www.datamintelligence.com/download-sample/multiple-sclerosis-therapeutics-market
Why This MS Approval Matters
Multiple sclerosis is not one uniform disease. Patients can experience relapsing disease, progressive disability, inflammatory lesions, worsening mobility, cognitive decline and fatigue in different patterns. Historically, the most commercially successful therapies focused on reducing relapse rates and MRI activity. That made sense because relapses were measurable, clinically visible and easier to study in trials. But many patients eventually enter a progressive phase where disability worsens even without recent relapses. That is secondary progressive multiple sclerosis. This is where treatment has been more difficult.
In non relapsing secondary progressive multiple sclerosis, the disease process becomes less visibly inflammatory and more connected to chronic immune activation inside the central nervous system, neurodegeneration and slow accumulation of disability. Cenrifki is important because it is designed to address that biology. Tolebrutinib is a Bruton’s tyrosine kinase inhibitor. BTK is involved in immune cell signaling, including B cells and myeloid cells. Sanofi has positioned Cenrifki as a brain penetrant therapy, which matters because progressive multiple sclerosis may be driven partly by immune activity inside the central nervous system. That makes the drug different from many traditional multiple sclerosis therapies. The commercial importance comes from the possibility that physicians may finally have a new option for patients whose disability is worsening without recent relapses.
Why Sanofi Needed This Win
The approval is also important for Sanofi’s broader pipeline story. Sanofi acquired Principia Biopharma in 2020 in a deal that gave it control of tolebrutinib. At the time, BTK inhibition looked like one of the most promising new mechanisms in multiple sclerosis. The path since then has been uneven.
Tolebrutinib faced clinical and regulatory setbacks, including challenges in relapsing multiple sclerosis and regulatory hesitation in the United States. Sanofi also recorded a major write down tied to the program after reduced expectations for approval. That context makes the EU approval more meaningful. It gives Sanofi a clear commercial path in Europe and helps rescue part of the strategic logic behind the original acquisition. For Sanofi, Cenrifki can now become a differentiated neuroscience asset rather than only a troubled pipeline program. It also supports the company’s effort to strengthen its research and development credibility. Sanofi has been working to improve its pipeline productivity and build more confidence around its next wave of growth drivers. Cenrifki gives the company a rare win in a difficult neurological disease area.
Why Europe Is Moving Differently From the U.S.
One of the most interesting aspects of the approval is the divergence between European and U.S. regulators. The European Commission approved Cenrifki after a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The U.S. FDA previously declined Sanofi’s application, stating that a favorable benefit risk profile could not be established.
This difference matters because it shows how regulators weigh progressive multiple sclerosis differently. In a high unmet need population, European regulators appear to have viewed the disability progression data as sufficient to support approval, while U.S. regulators remained more cautious. That does not mean one regulator is right and the other is wrong.
It means the evidence package sits in a complex area. Progressive multiple sclerosis is difficult to study. Disability progression is slower, endpoints can be harder to interpret and safety tolerance becomes especially important because patients may need long term treatment. For Sanofi, the EU approval creates an opportunity to generate real world evidence in Europe. That evidence could become important for physician adoption, payer discussions and future regulatory engagement in other markets.
The Competitive Landscape of MS Market
The multiple sclerosis market is already one of the most competitive areas in immunology and neurology. Major players include Roche, Novartis, Merck, Biogen, Bristol Myers Squibb and Sanofi. The market includes monoclonal antibodies, oral immunomodulators, sphingosine-1 phosphate receptor modulators and other disease modifying therapies. In relapsing multiple sclerosis, competition is intense. Physicians already have many treatment options, and new therapies must prove they offer meaningful advantages in efficacy, safety, convenience or patient selection.
Progressive multiple sclerosis is different. The need remains greater, especially for patients whose disability continues to worsen without active relapses. That is where Cenrifki could find its place. Sanofi does not need Cenrifki to dominate every multiple sclerosis segment. Its strategic value may come from serving a more specific group of patients where current options are limited. This is increasingly how specialty medicine markets work. The future is less about one drug treating the broadest possible population and more about finding the right patient segment where the mechanism creates the clearest clinical value.
What BTK Inhibitors Signal About the Pipeline
Cenrifki’s approval also matters because it keeps the BTK inhibitor strategy alive in multiple sclerosis. Several companies have been exploring BTK inhibitors in autoimmune and neurological diseases. The logic is compelling because BTK inhibition may affect both peripheral immune activity and central nervous system immune mechanisms, depending on the drug’s ability to enter the brain. That is especially relevant in progressive multiple sclerosis.
If disability progression is partly driven by chronic immune activity inside the central nervous system, then brain penetrant BTK inhibitors could become an important therapeutic class. But the class also carries questions. Safety will be closely watched. Liver toxicity, infection risk and long term immune effects will matter. Regulators, physicians and payers will also want to understand which patients benefit most. The next phase of the market will depend on whether BTK inhibitors can show durable disability benefit with an acceptable long term safety profile.
Cenrifki gives Sanofi a first mover position in Europe for this specific progressive multiple sclerosis segment. But the broader class still needs to prove itself.
Where the MS Market Is Headed
The multiple sclerosis market is moving toward more segmented and mechanism based treatment. Relapsing disease will remain competitive, with therapies differentiated by efficacy, safety, convenience and treatment sequencing. Progressive disease will become a bigger strategic focus because it represents a major unmet need and a more difficult therapeutic frontier.
The next phase of the market will be shaped by four priorities.
- Slowing disability progression.
- Targeting central nervous system immune activity.
- Improving long term safety.
- Identifying the right patients earlier.
Cenrifki sits directly at the center of these trends. If the drug performs well in real world European use, it could strengthen confidence in BTK inhibition and create a new treatment pathway for non relapsing secondary progressive multiple sclerosis. If safety concerns or reimbursement hurdles limit adoption, the approval may remain commercially narrower. Either way, the approval is strategically important because it changes the conversation. It shows that progressive multiple sclerosis is becoming a serious competitive target.
The Bigger Picture for Sanofi
Sanofi’s Cenrifki approval is more than a comeback moment for one drug. It is a signal that multiple sclerosis treatment is moving into a more complex and more clinically meaningful phase. The first major wave of multiple sclerosis innovation focused on reducing relapses. The next wave will focus on preventing disability.
For Sanofi, the EU approval gives Cenrifki a meaningful commercial opportunity and strengthens its neuroscience pipeline story. It shows that the future of the multiple sclerosis market will be defined by whether companies can slow the long-term progression that changes patients’ lives.
Read Complete Research Report: https://www.datamintelligence.com/research-report/multiple-sclerosis-therapeutics-market
Media Contact
Fabian Mathews
Business Development Manager
DataM Intelligence 4Market Research
[email protected]
Corporate Address: 2243 Rocoso TRL, Leander, TX 78641, USA
https://www.datamintelligence.com/